Drug treatments for spasticity.
Yelnik
A P
AP
Department of Physical and Rehabilitation Medicine, GH Lariboisière-F.-Widal, AP-HP, université Paris-7, 200, rue du Faubourg-Saint-Denis, 75010 Paris, France.
Simon
O
O
Bensmail
D
D
Chaleat-Valayer
E
E
Decq
P
P
Dehail
P
P
Quentin
V
V
Marque
P
P
Parratte
B
B
Pellas
F
F
Rousseaux
M
M
Trocello
J-M
JM
Uzzan
M
M
Dumarcet
N
N
D000284:Administration, Oral; D000328:Adult; D000438:Alcohols / Q000627:therapeutic use; D000465:Algorithms; D018726:Anti-Dyskinesia Agents / Q000627:therapeutic use*; D001418:Baclofen / Q000627:therapeutic use; D001905:Botulinum Toxins / Q000627:therapeutic use; D002648:Child; D003000:Clonidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D003663:Decision Trees; D006801:Humans; D007273:Injections, Intramuscular; D007278:Injections, Spinal; D009125:Muscle Relaxants, Central / Q000627:therapeutic use*; D009128:Muscle Spasticity / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D018579:Patient Selection; D019800:Phenol / Q000627:therapeutic use; D012449:Safety; D012597:Sclerosing Solutions / Q000627:therapeutic use; D016896:Treatment Outcome
D000438:Alcohols; D018726:Anti-Dyskinesia Agents; D009125:Muscle Relaxants, Central; D012597:Sclerosing Solutions; D019800:Phenol; C023754:tizanidine; D001905:Botulinum Toxins; D001418:Baclofen; D003000:Clonidine